With a global drive toward personalised precision medicines, a need has emerge for the development of diagnostic and prognostic technologies. Current health care systems do not possess the resources to address this deficit resulting in the field of precision medicine de-railing despite its significant benefits.With a greater understanding of cancer diagnosis, staging and disease progression present within todays oncology treatments, a movement away from the traditional “one size fits all” strategy has gained traction. Personalised oncology tailor’s treatment toward the individual based upon their tumour characteristics; boosting treatment effect, minimising unwanted side effects and ultimately improving patient quality of life. Tailored treatment plans place a greater emphasis upon the detection and monitoring of disease specific biomarkers for diagnostic and prognostic purposes, to aid in the determination and evaluation of patient treatment. The ability to monitor biomarker expression and correlate these to circulating blood concentration in real-time, could aid clinicians in determining therapeutic dosage while minimising side effects to healthy cells and tissue; made possible by continual adjustment of administered dose in conjunction with biomarker fluctuations.To this eval an innovative new sensing system is under investigation. This initial proof-of-concept study utilises the inherent advantages of electrochemiluminescence (ECL) toward the development of a point-of-care remote sensor which would facilitate real-time data rely to clinicians. The development of a continuous monitoring sensor would ultimately aim to increase the frequency of patient assessment, moving away from the routine interval imaging approach currently adopted, whilst in turn decreasing the number of hospital visitations a patient may have to undertake, a timely advantage given the current global pandemic. ECL is a powerful technique, whose employment within the medical device and bioanalytical fields only stands to offer huge benefits including portable instrumentation, improved sensitivity and increased operational simplicity. Despite its discovery in the 1960’s ECL has only in recent years seen an increased popularity within the wider analytical community. This is largely correlated to the increase in technology within the last decade which have facilitated the reduction in instrument size and complexity, so much so that today the technique can be performed through a modified smartphone. This research aims to introduce ECL to the wider analytical community, and encourage its employment within the pharmaceutical and clinical arenas, where to date its use is almost negligible.The combination of screen printed electrodes, with different metal luminophore’s and gold nanoparticles has facilitated the initial development of the proposed sensor. The use of a combination of different luminophores is one of the primary research goals, where the use of multi-metal ECL sensors will ultimately be employed. Preliminary research has displayed the unique characteristic of different metal complexes to offer alternative selectivities. Therefore, incorporation of a range of metals will ultimately provide the improved specificity required for employment within the diagnostic field. Utilising gemcitabine and leucovorin initially, the ability to detect these cancer therapies at clinically relevant ranges has provided a strong premise toward a multicolour multi-metal sensor array for the rapid determination of a multitude of species within biological matrices. With background interferents known to previously plague ECL point-of-care sensors negated through this unique multi-metal approach.This research represents a ground-breaking step change in enabling technology at the frontier of disease detection research and is hoped to form the foundations for the development of cutting-edge diagnostic ECL sensing devices. The ability to continuously and remotely monitor patients is currently very timely in light of the global pandemic, where the ability to minimise the number of hospital visits required will in turn minimise the risk of virus exposure to one of the most clinically vulnerable groups in society. Ultimately the development of such a remote point-of-care sensor only stands to offer a huge range of benefits not only to patients, but physicians, clinical and health care systems.